Angiogenesis markers after hepatic artery embolization of liver metastases in patients with neuroendocrine tumors Abstract #77

Introduction: In the event of diffuse hepatic metastases, hepatic artery embolization (HAE) can be a successful treatment option in patients with well-differentiated neuroendocrine tumors (WNET). Although there are suggestions of activation of the angiogenesis by HAE, no information is available about the development of growth factors caused by vascular obstruction with embolization.
Aim(s): To investigate angiogenesis activity following embolization by measuring of vascular endothelial growth factor (VEGF), endothelin-1 (ET) and C-terminal pro-Endothelin-1 (proET). To examine necrosis activity MonoTotal (MT), a cytokeratin marker, was measured.
Materials and methods: Between 2003 and 2008, 12 patients (M/F: 6/6, age (mean ± SD): 59 ± 9 years) were treated with transcatheter embolization. Blood was obtained before embolization and the days following this treatment during hospitalization. VEGF and ET were measured with ELISA kits (R&D Systems, Minneapolis, USA) and proET levels was measured with an immunoassay (BRAHMS AG; Hennigsdorf, Germany). MT was measured with an IRMA-assay (IDL Biotech AB, Bromma, Sweden).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MSc Catharina M Korse

To read results and conclusion, please login ...

Further abstracts you may be interested in

#25 Predictors of response to radio-embolization (TheraSphere ®) treatment of neuro-endocrine liver metastasis
Introduction: Neuroendocrine tumors (NET) frequently metastasize to the liver. Most patients have diffuse, and therefore incurable, disease. NET liver metastasis has been shown to respond to yttrium-90 microspheres therapy. This study aims to define factors that predict response to radio-embolization in patients with NET liver metastases.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Mazen Hassanain
#78 The diagnostic and prognostic value of elevated proGRP levels in well- and moderately differentiated neuroendocrine tumors
Introduction: Chromogranin A (CgA) is the most frequently used marker in well- (grade 1) and moderately (grade 2) differentiated NETs. Although CgA is a more sensitive marker than the 5-HIAA, which was widely used until the last decade, CgA has some limitations. False-positively elevated CgA may occur in renal impairment, atrophic gastritis and during treatment of proton-pump inhibitors. Progastrin-releasing peptide (proGRP) was recently reported as a promising tumor marker for small cell lung cancer. Limited data suggests that ProGRP may be a potential tumor marker in NE tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Msc Catharina M Korse
#87 Alterations of E-cadherin, beta-catenin and caveolin-1 expression in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NETs) comprise a heterogeneous group of neoplasm with different histological patterns and biological behavior. Only limited information is available on immunohistochemical prognostic factors of disease. Alterations in the cell-cell adhesion system are closely associated with cell invasion and metastasis in many malignancies, including those of endocrine origin. Abnormal expression of E-cadherin and beta-catenin has been reported to play an important role in these processes. Caveolin-1 has recently been identified as a tumor metastasis modifier factor, which might increase the cell metastasis potential through the interaction with E-cadherin. However, the role of caveolin-1 in GEP NETs cell invasion remains unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Vera V Delektorskaya
Authors: Delektorskaya V, Chemeris G, ...
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#133 Effectiveness of transarterial embolization of liver neuroendocrine metastases
Introduction: Neuroendocrine tumors (NETs) with diffuse liver metastases have a poor prognosis and prove difficult to palliate. Somatostatin analogues and chemotherapy have been used but often are poorly tolerated and may not provide symptom relief. Transarterial Embolization (TAE) is being increasingly used to improve symptom control and reduce tumor size. We looked at the last 5-year experience of TAE in patients with hepatic metastases from neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dalvinder S Mandair
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.